Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) Director Jeffrey W. Albers sold 11,033 shares of the firm’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $90.69, for a total value of $1,000,582.77. Following the sale, the director now directly owns 165,017 shares in the company, valued at $14,965,391.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Blueprint Medicines Stock Up 5.7 %
Shares of NASDAQ:BPMC opened at $94.79 on Thursday. Blueprint Medicines Co. has a 1 year low of $41.54 and a 1 year high of $101.00. The business has a 50 day simple moving average of $86.06 and a two-hundred day simple moving average of $72.75. The firm has a market capitalization of $5.80 billion, a PE ratio of -11.34 and a beta of 0.63. The company has a debt-to-equity ratio of 1.60, a current ratio of 3.76 and a quick ratio of 3.66.
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) last announced its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 191.56% and a negative net margin of 203.30%. The business had revenue of $71.96 million during the quarter, compared to analyst estimates of $67.34 million. During the same quarter in the previous year, the business earned ($2.65) earnings per share. The company’s revenue for the quarter was up 85.5% compared to the same quarter last year. On average, equities analysts predict that Blueprint Medicines Co. will post -5.42 EPS for the current year.
Wall Street Analyst Weigh In
Get Our Latest Analysis on BPMC
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Pinebridge Investments L.P. purchased a new stake in shares of Blueprint Medicines in the second quarter valued at approximately $46,000. Compass Wealth Management LLC purchased a new stake in shares of Blueprint Medicines in the fourth quarter valued at approximately $69,000. PNC Financial Services Group Inc. boosted its holdings in shares of Blueprint Medicines by 63.4% in the third quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 329 shares during the period. Van ECK Associates Corp boosted its holdings in shares of Blueprint Medicines by 28.4% in the fourth quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 193 shares during the period. Finally, Cutler Group LLC CA boosted its holdings in shares of Blueprint Medicines by 1,685.7% in the third quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 944 shares during the period.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Featured Stories
- Five stocks we like better than Blueprint Medicines
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Best Bear Market Funds: Top 3 Investment Options to Consider
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- What is Forex and How Does it Work?
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.